Analysts throw cold water on Exelixis and Roche's prostate cancer data, putting the pair a further step behind Novartis

Exelixis has blockbuster dreams for its Cabometyx drug, and it’s looking to capitalize in the prostate cancer market by combining it with Roche’s Tecentriq. But after a new data readout Monday drew concerns from analysts, its future in the area appears more cloudy.